UBS Lifts Johnson & Johnson Price Target to $320

Johnson & Johnson (JNJ) shares jumped approximately 1.2% on Wednesday to $274.395 after UBS raised its price target from $280 to $320.

This increase made J&J the Dow's biggest point booster in early trading, according to Barron's.

UBS maintained its 'Buy' rating for J&J, citing faster growth and more value hidden within the company's pharmaceutical pipeline.

The firm highlighted J&J's second-quarter results, which showed sales rising 6.6% to $25.3 billion, while management increased their 2026 sales midpoint to $101.1 billion and adjusted earnings guidance to $11.68 per share.